搜尋結果
Side effects. The most common side effects include fever, headache, nausea, muscle and joint pain, tenderness and pain at the injection site, tiredness, and feeling unwell. [4]
- AU: B1
- Intramuscular
- Covovax, Nuvaxovid
- SARS-CoV-2
Novavax's work is in competition for vaccine development among dozens of other companies. In January 2021, the company released phase III trials showing that it has 89% efficacy against Covid-19, and also provides strong immunity against new variants. [28] It has applied for emergency use in the US and UK but will be distributed in the UK first ...
- 1987; 36 years ago
- Gaithersburg, Maryland, U.S.
- 1,541 (2022)
- US$1.982 billion (2022)
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), the virus that causes coronavirus disease 2019 ( COVID‑19 ). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing ...
On 9 September, the second batch of the Pfizer–BioNTech COVID-19 vaccine, with 910,000 doses, arrived in Taiwan. Combined with the first batch, the 1.8 million dose of Pfizer-BioNTech COVID-19 vaccine will be used for the youth vaccination program, ranging from age 12 to 22.
The Matrix-M adjuvant is used in a number of vaccine candidates, including the malaria vaccine R21/Matrix-M, influenza vaccines, and in the approved Novavax COVID-19 vaccine. [5] [12] In 2021, the R21/Matrix-M malaria vaccine candidate showed a 77% efficacy over a 12-month period.
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...
